Article
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature.
Medical oncology (Northwood, London, England) - 28 Apr 2023
Ebeling Marcel, Scheurer Mario, Sakkas Andreas, Pietzka Sebastian, Schramm Alexander, Wilde Frank
Abstract excerpt
BACKGROUND: Ameloblastoma in 66% of the cases harbor a somatic mutation of the "mitogen-activated protein kinase" signaling pathway (BRAF V600E). In V600E mutations, BRAF is in the permanent "on" state and relays the growth-promoting signals independently of the EGFR pathway. Therefore, mutant BRAF represents a target for handful of new drugs. METHODS: We conducted a literature search, with the search terms...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.